US Pharma MarketingAmgen’s Repatha receives positive CHMP opinion for broader cardiovascular use
Amgen has received a positive opinion from the EMA’s CHMP for Repatha supporting its broader use prior to a first heart attack or stroke.
Amgen has received a positive opinion from the EMA’s CHMP for Repatha supporting its broader use prior to a first heart attack or stroke.
Source: Pharmaceutical Technology